Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
PainReform (PRFX)
NASDAQ:PRFX
Holding PRFX?
Track your performance easily
PRFX Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.73 - $80.64
Previous Close$3.2
Volume485.54K
Average Volume (3M)891.73K
Market Cap
$1.78M
Enterprise Value-$5.91M
Total Cash (Recent Filing)$8.03M
Total Debt (Recent Filing)$337.00K
Price to Earnings (P/E)―
Beta1.28
Next Earnings
Feb 28, 2025EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-8.29
Shares Outstanding1,171,041
10 Day Avg. Volume20,146,803
30 Day Avg. Volume891,728
Standard Deviation0.21
R-Squared0.02
Alpha-0.10
Financial Highlights & Ratios
Price to Book (P/B)0.17
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)N/A
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit5.90
Enterprise Value/Ebitda1.50
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusHold
Number of Analyst Covering1
PainReform News
PremiumMarket News
3 Penny Stocks to Watch Now, 11/21/24
PremiumCompany Announcements
PainReform’s PRF-110 Shows Promise in Initial Trial Results
PremiumCompany Announcements
PainReform Announces 1-for-4 Reverse Share SplitBulls Say, Bears Say
Bulls Say
Clinical OutcomesPatients were found to experience proper wound healing with no abnormalities in scar formation.
Product DevelopmentPRF-110 is being developed to compete with Exparel and Zynrelef, the two leading nonopioid therapies for post-operative pain.
Safety And EfficacyThe pharmacokinetic evaluations showed levels of ropivacaine in the blood were 10x lower than the levels required for toxic exposure, further supporting PRF-110’s safety.
Bears Say
Capital RequirementsPainReform may need additional capital to complete necessary studies, but there are concerns about the ability to raise capital given current market conditions.
Financial PerformanceThere is uncertainty about PainReform's ability to continue the development of PRF-110 due to capital constraints and lower revenue potential.
Market CompetitionThe recent approval of a generic version of Exparel, the market leader, impacts the market opportunity for PainReform's PRF-110.
---
Ownership Overview
―
Insiders
0.34% Mutual Funds
― Other Institutional Investors
99.66% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
PRFX FAQ
What was PainReform’s price range in the past 12 months?
PainReform lowest stock price was $1.73 and its highest was $80.64 in the past 12 months.
What is PainReform’s market cap?
Currently, no data Available
When is PainReform’s upcoming earnings report date?
PainReform’s upcoming earnings report date is Feb 28, 2025 which is in 97 days.
How were PainReform’s earnings last quarter?
Currently, no data Available
Is PainReform overvalued?
According to Wall Street analysts PainReform’s price is currently Overvalued.
Does PainReform pay dividends?
PainReform does not currently pay dividends.
What is PainReform’s EPS estimate?
PainReform’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does PainReform have?
PainReform has 556,613 shares outstanding.
What happened to PainReform’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of PainReform?
Currently, no hedge funds are holding shares in PRFX
---
PainReform Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-93.52%
12-Months-Change
Fundamentals
Return on Equity
-716.67%
Trailing 12-Months
Asset Growth
-62.64%
Trailing 12-Months
Company Description
PainReform
PainReform Ltd is a clinical-stage specialty pharmaceutical company. It is focused on the reformulation of established therapeutics. The company's product PRF-110 is based on the local anesthetic ropivacaine, targeting the post-operative pain relief market. PRF-110 is an oil-based, viscous, clear solution that is deposited directly into the surgical wound bed before closure to provide localized and extended post-operative analgesia.
---
PRFX Stock 12 Month Forecast
Average Price Target
―Technical Analysis
---